만성 림프구성 백혈병에 대한 최신 지견

키워드

참고문헌 (79)

1. Eichhorst B, "ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up", Ann Oncol., 19(Suppl 2), pp.ii60~ii62 (2008)
2. Dores GM, "Chronic lymphocytic leukaemia and small lymphocytic lymphoma : overview of the descriptive epidemiology", Br J Haematol, 139, pp.809~819 (2007)
3. 이혜원, "Nationwide Statistical Analysis of Lymphoid Malignancies in Korea", Cancer Research and Treatment, 50(1), pp.222~238 (2018), 대한암학회
4. Gunawardana C, "South Asian chronic lymphocytic leukaemia patients have more rapid disease progression in comparison to White patients", Br J Haematol, 142, pp.606~609 (2008)
5. Yunsuk Choi, "Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study", The Korean Journal of Internal Medicine, 36(1), pp.194~204 (2021), 대한내과학회[DOI]
6. Jang MA, "Chronic lymphocytic leukemia in Korean patients : frequent atypical immunophenotype and relatively aggressive clinical behavior", Int J Hematol, 97, pp.403~408 (2013)
7. Kim JA, "Genomic profile of chronic lymphocytic leukemia in Korea identified by targeted sequencing", PLoS One, 11, pp.e0167641~ (2016)
8. Nabhan C, "Chronic lymphocytic leukemia : a clinical review", JAMA, 312, pp.2265~2276 (2014)
9. Hallek M, "iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL", Blood, 131, pp.2745~2760 (2018)
10. Ratterman M, "Extramedullary chronic lymphocytic leukemia : systematic analysis of cases reported between 1975 and 2012", Leuk Res, 38, pp.299~303 (2014)
11. Hodgson K, "Chronic lymphocytic leukemia and autoimmunity : a systematic review", Haematologica, 96, pp.752~761 (2011)
12. Parikh SA, "How we treat Richter syndrome", Blood, 123, pp.1647~1657 (2014)
13. Rossi D, "Biology and treatment of Richter syndrome", Blood, 131, pp.2761~2772 (2018)
14. Marti GE, "Diagnostic criteria for monoclonal B-cell lymphocytosis", Br J Haematol, 130, pp.325~332 (2005)
15. Rawstron AC, "Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia", N Engl J Med, 359, pp.575~583 (2008)
16. Shanafelt TD, "Monoclonal B-cell lymphocytosis(MBL) : biology, natural history and clinical management", Leukemia, 24, pp.512~520 (2010)
17. Strati P, "Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia : diagnosis, natural history, and risk stratification", Blood, 126, pp.454~462 (2015)
18. Rai KR, "Clinical staging of chronic lymphocytic leukemia", Blood, 46, pp.219~234 (1975)
19. Binet JL, "A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis", Cancer, 48, pp.198~206 (1981)
20. Rai KR, "Chronic lymphocytic leukemia: recent progress and future directions", pp.253~264 (1987), Alan R. Liss
21. New prognostic markers in CLL, "Montserrat E.", Hematology Am Soc Hematol Educ Program, 279~284 (2006)
22. International CLL-IPI working group, "An international prognostic index for patients with chronic lymphocytic leukaemia(CLL-IPI) : a meta-analysis of individual patient data", Lancet Oncol, 17, pp.779~790 (2016)
23. Döhner H, "Genomic aberrations and survival in chronic lymphocytic leukemia", N Engl J Med, 343, pp.1910~1916 (2000)
24. Cramer P, "Prognostic factors in chronic lymphocytic leukemia-what do we need to know?", Nat Rev Clin Oncol, 8, pp.38~47 (2011)
25. Baliakas P, "Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia : a systematic reappraisal of classic cytogenetic data", Am J Hematol, 89, pp.249~255 (2014)
26. Thompson PA, "Complex karyotype is a stronger predictor than del(17p)for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens", Cancer, 121, pp.3612~3621 (2015)
27. Baliakas P, "Cytogenetic complexity in chronic lymphocytic leukemia : definitions, associations, and clinical impact", Blood, 133, pp.1205~1216 (2019)
28. Oscier DG, "Multivariate analysis of prognostic factors in CLL : clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors", Blood, 100, pp.1177~1184 (2002)
29. Hamblin TJ, "Unmutated Ig V(H)genes are associated with a more aggressive form of chronic lymphocytic leukemia", Blood, 94, pp.1848~1854 (1999)
30. Hu B, "Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients", Br J Haematol, 187, pp.307~318 (2019)
31. Hallek M, "Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma", Leuk Lymphoma, 22, pp.439~447 (1996)
32. Wierda WG, "Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment", J Clin Oncol, 27, pp.1637~1643 (2009)
33. Ahn IE, "Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib : development and validation of a four-factor prognostic model", J Clin Oncol, 39, pp.576~585 (2021)
34. Del Poeta G, "Clinical significance of CD38 expression in chronic lymphocytic leukemia", Blood, 98, pp.2633~2639 (2001)
35. Del Principe MI, "Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia", Blood, 108, pp.853~861 (2006)
36. Chen L, "Expression of ZAP-70is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia", Blood, 100, pp.4609~4614 (2002)
37. Kröber A, "Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia", J Clin Oncol, 24, pp.969~975 (2006)
38. Oscier DG, "The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial", Blood, 121, pp.468~475 (2013)
39. Nadeu F, "Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia", Blood, 127, pp.2122~2130 (2016)
40. Dighiero G, "Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia", N Engl J Med, 338, pp.1506~1514 (1998)
41. Rai KR, "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia", N Engl J Med, 343, pp.1750~1757 (2000)
42. Eichhorst BF, "Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia", Blood, 107, pp.885~891 (2006)
43. Knauf WU, "Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia", J Clin Oncol, 27, pp.4378~4384 (2009)
44. Niederle N, "Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia", Ann Hematol, 92, pp.653~660 (2013)
45. Hallek M, "Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia : a randomised, openlabel, phase 3 trial", Lancet, 376, pp.1164~1174 (2010)
46. Thompson PA, "Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia", Blood, 127, pp.303~309 (2016)
47. Fischer K, "Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia : a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group", J Clin Oncol, 30, pp.3209~3216 (2012)
48. Eichhorst B, "First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia(CLL10) : an international, open-label, randomised, phase 3, non-inferiority trial", Lancet Oncol, 17, pp.928~942 (2016)
49. Goede V, "Obinutuzumab as frontline treatment of chronic lymphocytic leukemia : updated results of the CLL11 study", Leukemia, 29, pp.1602~1604 (2015)
50. Byrd JC, "Randomized phase 2study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia", Blood, 127, pp.79~86 (2016)
51. Goede V, "Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions", N Engl J Med, 370, pp.1101~1110 (2014)
52. Lozanski G, "Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions", Blood, 103, pp.3278~3281 (2004)
53. Zhang J, "Targeting cancer with small molecule kinase inhibitors", Nat Rev Cancer, 9, pp.28~39 (2009)
54. Byrd JC, "Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia", N Engl J Med, 371, pp.213~223 (2014)
55. Burger JA, "Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia", N Engl J Med, 373, pp.2425~2437 (2015)
56. O'Brien S, "Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion(RESONATE-17) : a phase 2, open-label, multicentre study", Lancet Oncol, 17, pp.1409~1418 (2016)
57. Burger JA, "Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia", Blood, 133, pp.1011~1019 (2019)
58. Woyach JA, "Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL", N Engl J Med, 379, pp.2517~2528 (2018)
59. Chanan-Khan A, "Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma(HELIOS) : a randomised, double-blind, phase 3study", Lancet Oncol, 17, pp.200~211 (2016)
60. Moreno C, "Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia(iLLUMINATE) : a multicentre, randomised, open-label, phase 3 trial", Lancet Oncol, 20, pp.43~56 (2019)
61. Fraser G, "Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia", small lymphocytic lymphoma, 2019, pp.33, 969~980
62. Burger JA, "Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL", SLL : 5 years of follow-up from the phase 3 RESONATE-2study, 2020, pp.34, 787~798
63. Thurmes P, "Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia", Leuk Lymphoma, 49, pp.49~56 (2008)
64. Ghez D, "Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib", Blood, 131, pp.1955~1959 (2018)
65. Sharman JP, "Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia(ELEVATE TN) : a randomised, controlled, phase 3 trial", Lancet, 395, pp.1278~1291 (2020)
66. Brown JR, "Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed", refractory chronic lymphocytic leukemia, 2014, pp.123, 3390~3397
67. Furman RR, "Idelalisib and rituximab in relapsed chronic lymphocytic leukemia", N Engl J Med, 370, pp.997~1007 (2014)
68. Chao DT, "BCL-2 family : regulators of cell death", Annu Rev Immunol, 16, pp.395~419 (1998)
69. Roberts AW, "Targeting BCL2with venetoclax in relapsed chronic lymphocytic leukemia", N Engl J Med, 374, pp.311~322 (2016)
70. Stilgenbauer S, "Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion : a multicentre, open-label, phase 2 study", Lancet Oncol, 17, pp.768~778 (2016)
71. Coutre S, "Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy", Blood, 131, pp.1704~1711 (2018)
72. Seymour JF, "Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia", N Engl J Med, 378, pp.1107~1120 (2018)
73. Fischer K, "Venetoclax and obinutuzumab in patients with CLL and coexisting conditions", N Engl J Med, 380, pp.2225~2236 (2019)
74. Dreger P, "Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia : the EBMT transplant consensus", Leukemia, 21, pp.12~17 (2007)
75. Awan FT, "Current perspectives on therapy for chronic lymphocytic leukemia", Am Soc Clin Oncol Educ Book, 40, pp.320~329 (2020)
76. Langerbeins P, "The CLL12 trial protocol : a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression", Future Oncol, 11, pp.1895~1903 (2015)
77. Langerbeins P, "Ibrutinib versus placebo in patientswith asymptomatic, treatment-naïve early stage CLL: primaryendpoint results of the phase3 double-blind randomized CLL12trial", Hematol Oncol., 37(Suppl 2), pp.38~40 (2019)
78. Shanafelt TD, "Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia", N Engl J Med, 381, pp.432~443 (2019)
79. Zelenetz AD, "Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia : interim results from a phase 3, randomised, double-blind, placebo-controlled trial", Lancet Oncol, 18, pp.297~311 (2017)

관련 논문AI추천